<DOC>
	<DOCNO>NCT02935387</DOCNO>
	<brief_summary>Rheumatoid arthritis ( RA ) patient remission combination TNFinhibitors ( TNFi ) methotrexate ( MTX ) often express wish stop MTX treatment side effect . Given efficacy TNFi conceivable early RA patient remission methotrexate ( MTX ) /TNFi stepwise discontinuation MTX prior TNFi superior maintaining sustain remission reach drug free remission compare discontinuation TNFi prior MTX . Objective : To investigate whether taper MTX first , TNFi golimumab ( GOL ) , efficacious taper GOL first , MTX , sustain remission reach drug free remission . Study design : multicenter , open label clinical trial early RA patient . Remission induce open label treat-to-target ( T2T ) remission induction protocol clinical care : ( MTX , hydroxychloroquine ( HCQ ) , i.m . glucocorticoid ( GC ) , , remission , TNFi golimumab ( GOL ) ) ( phase I , 3/4th 1 year ) . Patients sustained remission MTX/GOL ( DAS28 &lt; 2.6 max 4 swollen joint 44 swollen joint count ( SJC ) 2 consecutive visit 3 month apart ) randomize taper either MTX first , GOL GOL first , MTX primary endpoint sustain ( drug free ) remission ( phase II , 1 year ) . During 1 year additional follow-up maintenance drug-free sustained remission investigate ( phase III ) . Study population : RA patient fulfil 2010 American College Rheumatology ( ACR ) /EUropean League Against Rheumatism ( EULAR ) criterion RA , symptom duration &lt; 12 month ; naïve anti-rheumatic drug glucocorticoid RA ; DAS28 ≥3.2 . Intervention : Patients sustain remission ( define DAS28 &lt; 2.6 max 4 swollen joint 44SJC ≥ 2 consecutive visit 3 month apart ) MTX/GOL end phase I ( 24 week treatment MTX/GOL ) randomize ratio 1:1 taper medication follow : - Taper stop GOL first 24 week , , still sustain remission , taper stop MTX 24 week - Taper stop MTX first 24 week , , still sustain remission , taper stop GOL 24 week The primary end point proportion patient sustain remission week 24 start taper either MTX GOL first . The main secondary end point proportion patient drug-free sustained remission , week 48 start tapering .</brief_summary>
	<brief_title>REMission INDuction Very Early Rheumatoid Arthritis</brief_title>
	<detailed_description>Secondary endpoint : Phase I ( Remission induction ) : - The proportion patient MTX/HCQ/GC remission , define DAS28 &lt; 2.6 , week 12 week 24 start treatment . - The proportion patient MTX/GOL sustain remission , define DAS28 &lt; 2.6 max 4 swollen joint 44SJC 2 consecutive visit 3 month apart , week 24 start GOL treatment . - Predictors remission upon treatment MTX , HCQ single injection i.m . GC ( e.g . smoking status , BMI , alcohol use , sex , disease duration , DAS28 , Rheumatoid Factor ( RF ) -status , Anti-citrullinated protein antibody ( ACPA ) -status , presence erosion ) - Predictors remission upon treatment MTX GOL ( e.g . smoking status , BMI , alcohol use , sex , disease duration , DAS28 , RF-status , ACPA-status , presence erosion ) Phase II ( Tapering ) : - The proportion patient sustain remission , define DAS28 &lt; 2.6 max 4 swollen joint 44SJC 2 consecutive visit 3 month apart , week 48 start taper MTX first , GOL GOL first , MTX . - The proportion patient drug-free sustained remission , define DAS28 &lt; 2.6 max 4 swollen joint 44SJC 2 consecutive visit 3 month apart anti-rheumatic treatment , week 48 start taper - Mean disease activity , use disease activity score assess 28 joint ( DAS28 ) , week 24 week 48 start taper - Mean functional ability , use Dutch consensus health assessment questionnaire ( HAQ ) , week 24 week 48 start taper - Mean quality life , use visual analogue scale ( VAS ) EuroQol 5 dimension ( EQ5D ) questionnaire , week 24 week 48 start taper - Mean anxiety depression ( use Hospital Anxiety Depression Scale ( HADS ) ) , week 24 week 48 start taper - Mean fatigue ( use Functional Assessment Chronic Illness Therapy Fatigue ( FACIT-F ) ) , week 24 week 48 start taper - The proportion serious adverse event ( SAEs ) two taper strategy 24 48 week . - The time remission ( DAS28 &lt; 2.6 ) retreatment last effective dose upon flare taper MTX/GOL . Phase III ( Follow-up ) : - The proportion patient drug-free sustained remission , define DAS28 &lt; 2.6 max 4 swollen joint 44SJC 2 consecutive visit 3 month apart anti-rheumatic treatment , week 48 discontinuation MTX GOL - The time remission , define DAS28 &lt; 2.6 , retreatment clinical care upon flare - The proportion serious adverse event ( SAEs ) two taper strategy week 24 week 48 . Phase II III : - Cost per extra patient remission week 96 start tapering ( end phase III ) - Cost per Quality Adjusted life Year ( QALY ) gain week 96 start tapering ( end phase III ) Overall : - The sensitivity predictive value patient report Routine Assessment Patient Index Data 3 ( RAPID3 ) detect remission flare</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Fulfilling 2010 ACR/EULAR criterion RA . Patient report symptom duration &lt; 12 month Naïve DMARD biological treatment Naïve previous use glucocorticoid RA DAS28 ≥3.2 Being pregnant nursing woman woman child bear potential without ( adequate ) use contraception Having inflammatory rheumatic disease RA , except secondary Sjögren 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Very early rheumatoid arthritis</keyword>
</DOC>